| 04/27/2026 3:00 PM | Vor Biopharma (1817229) Filer | Form DEF 14A | |
| 04/27/2026 3:01 PM | Vor Biopharma (1817229) Filer | Form DEFA14A | |
| 04/27/2026 3:02 PM | Vor Biopharma (1817229) Filer | Form ARS | |
| 04/24/2026 5:12 PM | Kolchinsky Peter (1384859) Reporting RA Capital Healthcare Fund LP (1315082) Reporting RA CAPITAL MANAGEMENT, L.P. (1346824) Reporting Shah Rajeev M. (1619841) Reporting Vor Biopharma (1817229) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/21/2026 6:04 PM | Kolchinsky Peter (1384859) Reporting RA Capital Healthcare Fund LP (1315082) Reporting RA CAPITAL MANAGEMENT, L.P. (1346824) Reporting Shah Rajeev M. (1619841) Reporting Vor Biopharma (1817229) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/21/2026 6:05 PM | RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by Vor Biopharma (1817229) Subject | Form SCHEDULE 13D/A | |
| 04/15/2026 4:29 PM | Kolchinsky Peter (1384859) Reporting RA Capital Healthcare Fund LP (1315082) Reporting RA CAPITAL MANAGEMENT, L.P. (1346824) Reporting Shah Rajeev M. (1619841) Reporting Vor Biopharma (1817229) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/15/2026 4:31 PM | RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by Vor Biopharma (1817229) Subject | Form SCHEDULE 13D/A | |
| 04/10/2026 5:23 PM | Kolchinsky Peter (1384859) Reporting RA Capital Healthcare Fund LP (1315082) Reporting RA CAPITAL MANAGEMENT, L.P. (1346824) Reporting Shah Rajeev M. (1619841) Reporting Vor Biopharma (1817229) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/10/2026 5:25 PM | RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by Vor Biopharma (1817229) Subject | Form SCHEDULE 13D/A | |
| 04/09/2026 7:02 PM | Sokolove Jeremy Brett (2124648) Reporting Vor Biopharma (1817229) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
Get the Latest News and Ratings for VOR and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Vor Biopharma and its competitors with MarketBeat's FREE daily newsletter.
|
| 04/08/2026 5:45 PM | RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by Vor Biopharma (1817229) Subject | Form SCHEDULE 13D/A | |
| 04/06/2026 5:51 PM | Kolchinsky Peter (1384859) Reporting RA Capital Healthcare Fund LP (1315082) Reporting RA CAPITAL MANAGEMENT, L.P. (1346824) Reporting Shah Rajeev M. (1619841) Reporting Vor Biopharma (1817229) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/01/2026 4:29 PM | TCG Crossover GP II, LLC (1969280) Filed by Vor Biopharma (1817229) Subject | Form SCHEDULE 13G | |
| 04/01/2026 4:15 PM | TCG Crossover Fund II, L.P. (1969281) Reporting TCG Crossover Fund III, L.P. (2062644) Reporting TCG Crossover GP II, LLC (1969280) Reporting TCG Crossover GP III, LLC (2062816) Reporting Vor Biopharma (1817229) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 04/01/2026 4:09 PM | RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by Vor Biopharma (1817229) Subject | Form SCHEDULE 13D/A | |
| 03/30/2026 7:03 AM | Vor Biopharma (1817229) Filer | Form 10-K Annual report pursuant to Section 13 or 15(d) | |
| 03/30/2026 7:06 AM | Vor Biopharma (1817229) Filer | Form S-8 Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
| 03/27/2026 7:03 AM | Vor Biopharma (1817229) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 03/16/2026 3:15 PM | RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by Vor Biopharma (1817229) Subject | Form SCHEDULE 13D/A | |
| 02/17/2026 5:59 PM | Verve Capital Ltd (2088344) Filed by Vor Biopharma (1817229) Subject | Form SCHEDULE 13G/A | |
| 02/17/2026 5:22 PM | Venrock Healthcare Capital Partners III, L.P. (1738048) Filed by Vor Biopharma (1817229) Subject | Form SCHEDULE 13G/A | |
| 02/17/2026 3:13 PM | GREAT POINT PARTNERS LLC (1281446) Filed by Vor Biopharma (1817229) Subject | Form SCHEDULE 13G/A | |
| 02/13/2026 6:47 PM | Qiming Venture Partners VIII-HC, L.P. (1910025) Filed by Vor Biopharma (1817229) Subject | Form SCHEDULE 13G/A | |
| 02/05/2026 12:40 PM | FMR LLC (315066) Filed by Vor Biopharma (1817229) Subject | Form SCHEDULE 13G/A | |
| 02/04/2026 11:15 PM | Vor Biopharma (1817229) Filer | Form EFFECT | |
| 01/29/2026 3:14 PM | Vor Biopharma (1817229) Filer | Form S-3 Registration statement under Securities Act of 1933 | |
| 01/12/2026 8:55 AM | Vor Biopharma (1817229) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 12/23/2025 3:05 PM | ForGrowth III PA B.V. (2050902) Filed by Vor Biopharma (1817229) Subject | Form SCHEDULE 13D | |
| 12/19/2025 5:58 PM | Kolchinsky Peter (1384859) Reporting RA Capital Healthcare Fund LP (1315082) Reporting RA CAPITAL MANAGEMENT, L.P. (1346824) Reporting Shah Rajeev M. (1619841) Reporting Vor Biopharma (1817229) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/19/2025 5:17 PM | Joustra Wouter (1897813) Reporting Vor Biopharma (1817229) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/19/2025 5:04 PM | Levin Andrew David (1867539) Reporting Vor Biopharma (1817229) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 12/19/2025 5:07 PM | Joustra Wouter (1897813) Reporting Vor Biopharma (1817229) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 12/19/2025 5:14 PM | Levin Andrew David (1867539) Reporting Vor Biopharma (1817229) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/19/2025 3:40 PM | Frazier Life Sciences Public Fund, L.P. (1863769) Filed by Vor Biopharma (1817229) Subject | Form SCHEDULE 13G | |
| 12/18/2025 5:31 PM | RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by Vor Biopharma (1817229) Subject | Form SCHEDULE 13D/A | |
| 12/18/2025 3:00 PM | Vor Biopharma (1817229) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 12/09/2025 6:58 AM | Vor Biopharma (1817229) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 12/09/2025 7:00 AM | Kress Jean-Paul (1654979) Reporting Vor Biopharma (1817229) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/09/2025 7:00 AM | Vor Biopharma (1817229) Issuer Zuraw Qing Che (2079210) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/09/2025 7:00 AM | Mahatme Sandesh (1511034) Reporting Vor Biopharma (1817229) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
|
| 11/18/2025 3:30 PM | Paradigm Biocapital Advisors LP (1855655) Filed by Vor Biopharma (1817229) Subject | Form SCHEDULE 13G | |
| 11/14/2025 5:13 PM | RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by Vor Biopharma (1817229) Subject | Form SCHEDULE 13D/A | |
| 11/13/2025 3:02 PM | Vor Biopharma (1817229) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 11/12/2025 6:03 AM | Vor Biopharma (1817229) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 11/12/2025 5:08 AM | Vor Biopharma (1817229) Filer | Form 424B5 | |
| 11/07/2025 10:13 AM | FMR LLC (315066) Filed by Vor Biopharma (1817229) Subject | Form SCHEDULE 13G | |
| 11/03/2025 7:02 AM | Vor Biopharma (1817229) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 10/30/2025 5:40 PM | Kolchinsky Peter (1384859) Reporting RA Capital Healthcare Fund LP (1315082) Reporting RA CAPITAL MANAGEMENT, L.P. (1346824) Reporting Shah Rajeev M. (1619841) Reporting Vor Biopharma (1817229) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 10/30/2025 5:42 PM | RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by Vor Biopharma (1817229) Subject | Form SCHEDULE 13D/A | |
| 10/28/2025 3:37 PM | Vor Biopharma (1817229) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 10/27/2025 7:04 PM | Kolchinsky Peter (1384859) Reporting RA Capital Healthcare Fund LP (1315082) Reporting RA CAPITAL MANAGEMENT, L.P. (1346824) Reporting Shah Rajeev M. (1619841) Reporting Vor Biopharma (1817229) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 10/27/2025 7:06 PM | RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by Vor Biopharma (1817229) Subject | Form SCHEDULE 13D/A | |
| 10/22/2025 6:48 PM | Kolchinsky Peter (1384859) Reporting RA Capital Healthcare Fund LP (1315082) Reporting RA CAPITAL MANAGEMENT, L.P. (1346824) Reporting RA Capital Nexus Fund, L.P. (1780117) Reporting Shah Rajeev M. (1619841) Reporting Vor Biopharma (1817229) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 10/21/2025 4:45 PM | Hoffman Reid (1519339) Reporting Reprogrammed Interchange LLC (2050755) Reporting Vor Biopharma (1817229) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 10/20/2025 5:58 PM | RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by Vor Biopharma (1817229) Subject | Form SCHEDULE 13D/A | |
| 10/17/2025 5:33 PM | Hoffman Reid (1519339) Reporting Reprogrammed Interchange LLC (2050755) Reporting Vor Biopharma (1817229) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 10/17/2025 5:36 PM | Reprogrammed Interchange LLC (2050755) Filed by Vor Biopharma (1817229) Subject | Form SCHEDULE 13D/A | |
| 10/17/2025 5:03 PM | Kolchinsky Peter (1384859) Reporting RA Capital Healthcare Fund LP (1315082) Reporting RA CAPITAL MANAGEMENT, L.P. (1346824) Reporting RA Capital Nexus Fund, L.P. (1780117) Reporting Shah Rajeev M. (1619841) Reporting Vor Biopharma (1817229) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 10/17/2025 4:11 PM | RA Capital Healthcare Fund LP (1315082) Reporting Vor Biopharma (1817229) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 10/17/2025 4:14 PM | RA Capital Nexus Fund, L.P. (1780117) Reporting Vor Biopharma (1817229) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 10/16/2025 4:33 PM | RA Capital Nexus Fund, L.P. (1780117) Reporting Vor Biopharma (1817229) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 10/16/2025 4:21 PM | RA Capital Healthcare Fund LP (1315082) Reporting Vor Biopharma (1817229) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 10/16/2025 3:45 PM | Reprogrammed Interchange LLC (2050755) Filed by Vor Biopharma (1817229) Subject | Form SCHEDULE 13D/A | |
| 10/15/2025 5:32 PM | Hoffman Reid (1519339) Reporting Reprogrammed Interchange LLC (2050755) Reporting Vor Biopharma (1817229) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 10/15/2025 4:54 PM | RA Capital Healthcare Fund LP (1315082) Reporting Vor Biopharma (1817229) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 10/15/2025 5:05 PM | RA Capital Nexus Fund, L.P. (1780117) Reporting Vor Biopharma (1817229) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 10/10/2025 4:51 PM | Hoffman Reid (1519339) Reporting Reprogrammed Interchange LLC (2050755) Reporting Vor Biopharma (1817229) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 10/10/2025 4:52 PM | Reprogrammed Interchange LLC (2050755) Filed by Vor Biopharma (1817229) Subject | Form SCHEDULE 13D/A | |
| 10/08/2025 4:20 PM | Hoffman Reid (1519339) Reporting Reprogrammed Interchange LLC (2050755) Reporting Vor Biopharma (1817229) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 10/08/2025 4:24 PM | Reprogrammed Interchange LLC (2050755) Filed by Vor Biopharma (1817229) Subject | Form SCHEDULE 13D/A | |
| 10/06/2025 4:20 PM | Reprogrammed Interchange LLC (2050755) Filed by Vor Biopharma (1817229) Subject | Form SCHEDULE 13D/A | |
| 10/03/2025 8:12 PM | Hoffman Reid (1519339) Reporting Reprogrammed Interchange LLC (2050755) Reporting Vor Biopharma (1817229) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 09/26/2025 7:18 AM | Verve Capital Ltd (2088344) Filed by Vor Biopharma (1817229) Subject | Form SCHEDULE 13G | |
| 09/25/2025 7:34 PM | Venrock Healthcare Capital Partners III, L.P. (1738048) Filed by Vor Biopharma (1817229) Subject | Form SCHEDULE 13G | |
| 09/24/2025 3:57 PM | Vor Biopharma (1817229) Filer | Form S-3 Registration statement under Securities Act of 1933 | |
| 09/24/2025 3:59 PM | Vor Biopharma (1817229) Filer | Form S-8 Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
| 09/23/2025 3:00 PM | ForGrowth III PA B.V. (2050902) Filed by Vor Biopharma (1817229) Subject | Form SCHEDULE 13G | |
| 09/22/2025 3:56 PM | Kolchinsky Peter (1384859) Reporting RA Capital Healthcare Fund LP (1315082) Reporting RA CAPITAL MANAGEMENT, L.P. (1346824) Reporting RA Capital Nexus Fund, L.P. (1780117) Reporting Shah Rajeev M. (1619841) Reporting Vor Biopharma (1817229) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 09/19/2025 3:53 PM | RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by Vor Biopharma (1817229) Subject | Form SCHEDULE 13D/A | |
| 09/18/2025 7:40 PM | Hoffman Reid (1519339) Reporting Reprogrammed Interchange LLC (2050755) Reporting Vor Biopharma (1817229) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 09/17/2025 8:00 AM | Vor Biopharma (1817229) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 09/15/2025 4:17 PM | Hoffman Reid (1519339) Reporting Reprogrammed Interchange LLC (2050755) Reporting Vor Biopharma (1817229) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 09/12/2025 6:07 PM | Reprogrammed Interchange LLC (2050755) Filed by Vor Biopharma (1817229) Subject | Form SCHEDULE 13D/A | |
| 09/10/2025 7:27 PM | Hoffman Reid (1519339) Reporting Reprogrammed Interchange LLC (2050755) Reporting Vor Biopharma (1817229) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 09/10/2025 3:10 PM | Reed Sarah Burgess (2085062) Reporting Vor Biopharma (1817229) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 09/10/2025 3:15 PM | Kolchinsky Peter (1384859) Reporting RA Capital Healthcare Fund LP (1315082) Reporting RA CAPITAL MANAGEMENT, L.P. (1346824) Reporting RA Capital Nexus Fund, L.P. (1780117) Reporting Shah Rajeev M. (1619841) Reporting Vor Biopharma (1817229) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 09/09/2025 5:04 PM | Reprogrammed Interchange LLC (2050755) Filed by Vor Biopharma (1817229) Subject | Form SCHEDULE 13D/A | |
| 09/08/2025 8:19 PM | Reed Sarah Burgess (2085062) Reporting Vor Biopharma (1817229) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 09/05/2025 5:51 PM | Hoffman Reid (1519339) Reporting Reprogrammed Interchange LLC (2050755) Reporting Vor Biopharma (1817229) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 09/03/2025 12:50 PM | Reprogrammed Interchange LLC (2050755) Reporting Vor Biopharma (1817229) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
|
| 09/02/2025 9:43 AM | Vor Biopharma (1817229) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 08/29/2025 5:30 PM | Reprogrammed Interchange LLC (2050755) Filed by Vor Biopharma (1817229) Subject | Form SCHEDULE 13D/A | |
| 08/29/2025 5:05 PM | Hoffman Reid (1519339) Reporting Reprogrammed Interchange LLC (2050755) Reporting Vor Biopharma (1817229) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 08/27/2025 4:25 PM | Hoffman Reid (1519339) Reporting Reprogrammed Interchange LLC (2050755) Reporting Vor Biopharma (1817229) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 08/27/2025 11:34 AM | Vor Biopharma (1817229) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 08/27/2025 7:19 AM | Vor Biopharma (1817229) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 08/27/2025 6:38 AM | Vor Biopharma (1817229) Filer | Form 424B5 | |
| 08/08/2025 7:55 AM | Vor Biopharma (1817229) Filer | Form DEF 14A | |
| 08/06/2025 11:19 AM | FMR LLC (315066) Filed by Vor Biopharma (1817229) Subject | Form SCHEDULE 13G/A | |